Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis

NCT02019056 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Alcoholic Fatty Liver Disease
Alcoholic Hepatitis

Interventions

DRUG: Placebo /bid P.O
DRUG: MG-1
DRUG: MG-2 : MG1000mg, Placebo /bid P.O
DRUG: metadoxine

Sponsor

PharmaKing